ES2154263T3 - Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli. - Google Patents

Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli.

Info

Publication number
ES2154263T3
ES2154263T3 ES92918016T ES92918016T ES2154263T3 ES 2154263 T3 ES2154263 T3 ES 2154263T3 ES 92918016 T ES92918016 T ES 92918016T ES 92918016 T ES92918016 T ES 92918016T ES 2154263 T3 ES2154263 T3 ES 2154263T3
Authority
ES
Spain
Prior art keywords
polisacarido
coli
vaccines
protein
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918016T
Other languages
English (en)
Inventor
Stanley J Cryz
Emil P Furer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2154263T3 publication Critical patent/ES2154263T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN METODO PARA PRODUCIR UNA VACUNA E. COLI Y LA VACUNA ASI PRODUCIDA. EL METODO IMPLICA PURIFICAR UN LIPOPOLISACARIDO DE LA E. COLI QUE EXPRESA CADENAS COMPLETAS O-POLISACARIDAS; AISLAR LA REGION O-POLISACARIDA DE LA MOLECULA LIPOPOLISACARIDA POR HIDROLISIS EN ACIDO ACETICO DILUIDO Y PURIFICARLO ESENCIALMENTE LIBRE DE LIPIDOS A; Y ACOPLAR COVALENTEMENTE EL O-POLISACARIDO LIPIDO A-LIBRE VIA AL MENOS UN GRUPO CARBOXILO O HIDROXILO DEL POLISACARIDO EN UNA PROTEINA PORTADORA. LAS VACUNAS POLIVALENTES SE PREPARAN AL COMBINAR DOS O MAS VACUNAS MONOVALENTES PARA DIFERENTES SEROTIPOS PREPARADAS DE ACUERDO A LA INVENCION. LA CUAL DESCRIBE LOS CONJUGADOS UTILIZADOS EN LAS VACUNAS QUE SON LA REGION O-POLISACARIDA DE UNA MOLECULA E. COLI LIPOPOLISACARIDA ACOPLADA COVALENTEMENTE A UNA PROTEINA PORTADORA.
ES92918016T 1991-08-12 1992-08-11 Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli. Expired - Lifetime ES2154263T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/743,787 US5370872A (en) 1991-08-12 1991-08-12 Escherichia coliO-polysaccharide-protein conjugate vaccine

Publications (1)

Publication Number Publication Date
ES2154263T3 true ES2154263T3 (es) 2001-04-01

Family

ID=24990179

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92918016T Expired - Lifetime ES2154263T3 (es) 1991-08-12 1992-08-11 Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli.

Country Status (12)

Country Link
US (1) US5370872A (es)
EP (1) EP0598818B1 (es)
JP (1) JP2763960B2 (es)
AT (1) ATE198989T1 (es)
AU (1) AU669854B2 (es)
CA (1) CA2115564C (es)
DE (1) DE69231673T2 (es)
DK (1) DK0598818T3 (es)
ES (1) ES2154263T3 (es)
GR (1) GR3035662T3 (es)
WO (1) WO1993003765A1 (es)
ZA (1) ZA926063B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
KR100333113B1 (ko) * 1993-07-27 2002-11-27 시에스엘 리미티드 헬리코박터피롤리관련위십이지장질환의치료방법
US6872398B2 (en) * 1995-12-22 2005-03-29 The United States Of America As Represented By The Secretary Of The Army Conjugate vaccine against gram-negative bacterial infections
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
WO1998026799A1 (en) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
JP2004520001A (ja) * 1999-05-18 2004-07-08 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 複合糖質の製造
US7749511B2 (en) * 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
WO2001078787A2 (en) * 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
US20030096281A1 (en) * 2001-09-14 2003-05-22 Ganesh Venkataraman Methods of making glycomolecules with enhanced activities and uses thereof
WO2007078615A2 (en) * 2005-12-15 2007-07-12 Cavit Sciences, Inc Methods and compositions for treatment of cancer
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
WO2010083477A2 (en) 2009-01-16 2010-07-22 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
JP6590413B2 (ja) * 2014-02-06 2019-10-16 エックスフォー・ファーマシューティカルズ（オーストリア）ゲーエムべーハー 大腸菌特異的抗体配列
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
IL308201A (en) 2020-09-17 2024-01-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US5034516A (en) * 1987-08-04 1991-07-23 University Of Ottawa Synthetic antigens of sialic acid and derivatives thereof
AU5675790A (en) * 1989-05-09 1990-11-29 Cetus Corporation Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria

Also Published As

Publication number Publication date
AU2464192A (en) 1993-03-16
ZA926063B (en) 1993-05-19
EP0598818A1 (en) 1994-06-01
AU669854B2 (en) 1996-06-27
CA2115564C (en) 2002-01-22
WO1993003765A1 (en) 1993-03-04
DE69231673D1 (de) 2001-03-08
DK0598818T3 (da) 2001-03-19
DE69231673T2 (de) 2001-06-07
ATE198989T1 (de) 2001-02-15
GR3035662T3 (en) 2001-06-29
EP0598818A4 (en) 1995-04-05
US5370872A (en) 1994-12-06
CA2115564A1 (en) 1993-03-04
EP0598818B1 (en) 2001-01-31
JP2763960B2 (ja) 1998-06-11
JPH06510530A (ja) 1994-11-24

Similar Documents

Publication Publication Date Title
ES2154263T3 (es) Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli.
ES2084827T3 (es) Composiciones de vacuna mejoradas.
BR9510263A (pt) Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas
BR9605153A (pt) Vacina de combinação para uso na proteção de galináceos contra a doença de newcastle kit de vacinação para imunizar galináceos contra a doença de newcastle e processo para a prevenção da doença de newcastle em galináceos
ATE217196T1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
ES2065303T5 (es) Procedimiento de diagnosis y vacuna especifica.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
EE200100203A (et) Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ES2071288T3 (es) Vacuna mejorada de conjugado de polisacarido de meningococos.
DE69527202D1 (de) Proteinartige adjuvantien
BR9608612A (pt) Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
ATE196605T1 (de) Gruppe a streptokokkenpolysaccharide immunogen- zusammensetzungen und verfahren
PT83096B (pt) Processo para a preparacao de vacinas conjugadas contendo polissacaridos e proteinas contra infeccoes provocadas por bacterias gram-negativas
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
ES2181695T3 (es) Vacuna recombinante contra la pleuroneumonia porcina.
ES2124701T3 (es) Composiciones de vacunas.
CO5300406A1 (es) Vacuna
BR9709993A (pt) Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
PT94030A (pt) Processo de preparacao de antigenios protectores contra as infeccoes e efeitos toxidos de bordetella
ES2067710T3 (es) Compuestos no ionicos yodados, su procedimiento de preparacion y productos de contraste que contienen los mismos.
DE3750549D1 (de) Impfstoff gegen schweinedysenterie.
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 598818

Country of ref document: ES